Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/37117
Tipo
ArtículoDerechos de autor
Acceso abierto
Fecha del embargo
2020-11-18
Colecciones
- INI - Artigos de Periódicos [3399]
Metadatos
Mostrar el registro completo del ítem
THERAPY FOR OCULAR TOXOPLASMOSIS
Ocular toxoplasmosis
Recurrences
Steroids
Therapy
Treatment
Uveitis
Afiliación
Universidad del Quindío. Centro de Investigaciones Biomédicas. Grupo de Estudio en Parasitología Molecular. Armenia, Colombia.
King’s College London. St. Thomas’ Campus. Rayne Institute, Department of Academic Ophthalmology. London, UK.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Duke Eye Center. Duke Reading Center. Durham, NC, USA.
Universidad del Quindío. Centro de Investigaciones Biomédicas. Grupo de Estudio en Parasitología Molecular. Armenia, Colombia.
King’s College London. St. Thomas’ Campus. Rayne Institute, Department of Academic Ophthalmology. London, UK.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Duke Eye Center. Duke Reading Center. Durham, NC, USA.
Universidad del Quindío. Centro de Investigaciones Biomédicas. Grupo de Estudio en Parasitología Molecular. Armenia, Colombia.
Resumen en ingles
Purpose: To review current evidence for the treatment of ocular toxoplasmosis (OT). Design: Narrative review and expert recommendations. Methods: Meta-analysis and selected original articles from the medical literature were reviewed critically. Expert recommendations were analyzed. Results: Numerous observational studies suggest a benefit of short-term antimicrobial therapy for toxoplasmic retinochoroiditis in immunocompetent patients, although its efficacy has not been proven in randomized clinical trials. A randomized clinical trial revealed that intermittent trimethoprim/sulfamethoxazole treatment could decrease the rate of recurrence in high-risk patients. Intravitreal injection of clindamycin and dexamethasone was an acceptable alternative to the classic treatment for OT in a randomized clinical trial. Conclusions: Opinions about therapy differ and controversy remains about its type, efficacy, and length. Intravitreal therapy may be promising for OT. A recent description of the presence of parasitemia in patients with active and inactive ocular toxoplasmosis raises new questions that need to be explored.
Palabras clave en ingles
AntibioticsOcular toxoplasmosis
Recurrences
Steroids
Therapy
Treatment
Uveitis
Compartir